Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + SOX in ctDNA-positive Stage III Gastric Cancer
NCT06939439Phase 3Active, not recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Disease-Free Survival at 1 year. Started Dec 2024; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06939439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06939439.